Irbotens

Irbesartan, the active ingredient in Irbotens, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and related cardiovascular conditions in adults. By selectively blocking AT1 receptors, it helps lower vascular resistance and reduces fluid retention, supporting patients with hypertension, diabetic kidney disease, or heart failure.

GNH USA supplies Irbotens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker used to treat conditions related to the renin‑angiotensin system. - Hypertension: lowers blood pressure and reduces risk of cardiovascular events. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: improves symptoms and reduces hospitalizations in patients with reduced ejection fraction.

Irbesartan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness: light‑headed sensation, especially after standing. - Headache: mild to moderate pain in the head. - Fatigue: feeling unusually tired or weak. - Hyperkalemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may compromise breathing. - Renal impairment: worsening kidney function, indicated by increased serum creatinine. - Hepatic injury: signs of liver damage such as jaundice or elevated enzymes. - Severe hypotension: marked drop in blood pressure causing fainting.

When prescribing Irbesartan, clinicians should consider several safety considerations to minimize risk. - Renal function: monitor serum creatinine and potassium, especially in patients with pre‑existing kidney disease. - Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Hyperkalemia: avoid use with potassium‑sparing diuretics or supplements. - Volume depletion: assess for dehydration before initiating therapy. - Drug interactions: review concomitant medications that affect the renin‑angiotensin system. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: combined use may cause excessive potassium rise and renal dysfunction. - Potassium‑rich supplements or potassium‑sparing diuretics: increase risk of hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may enhance hypotensive effect; monitor blood pressure. - Lithium: increased lithium levels; monitor for toxicity. - Cyclosporine or tacrolimus: may increase serum creatinine; assess renal function.